SPRC vs. TMBR, ASLN, PBLA, EVFM, SEEL, BDRX, HSTO, ATHX, PRFX, and GRI
Should you be buying SciSparc stock or one of its competitors? The main competitors of SciSparc include Timber Pharmaceuticals (TMBR), ASLAN Pharmaceuticals (ASLN), Panbela Therapeutics (PBLA), Evofem Biosciences (EVFM), Seelos Therapeutics (SEEL), Biodexa Pharmaceuticals (BDRX), Histogen (HSTO), Athersys (ATHX), PainReform (PRFX), and GRI Bio (GRI). These companies are all part of the "pharmaceutical preparations" industry.
SciSparc (NASDAQ:SPRC) and Timber Pharmaceuticals (NYSE:TMBR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, dividends, community ranking, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.
SciSparc has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500. Comparatively, Timber Pharmaceuticals has a beta of 0.03, suggesting that its stock price is 97% less volatile than the S&P 500.
SciSparc has higher revenue and earnings than Timber Pharmaceuticals.
25.1% of SciSparc shares are held by institutional investors. Comparatively, 3.6% of Timber Pharmaceuticals shares are held by institutional investors. 1.5% of SciSparc shares are held by company insiders. Comparatively, 1.6% of Timber Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
In the previous week, SciSparc had 4 more articles in the media than Timber Pharmaceuticals. MarketBeat recorded 4 mentions for SciSparc and 0 mentions for Timber Pharmaceuticals. SciSparc's average media sentiment score of 0.22 beat Timber Pharmaceuticals' score of 0.00 indicating that SciSparc is being referred to more favorably in the media.
SciSparc's return on equity of 0.00% beat Timber Pharmaceuticals' return on equity.
Timber Pharmaceuticals received 5 more outperform votes than SciSparc when rated by MarketBeat users. Likewise, 77.78% of users gave Timber Pharmaceuticals an outperform vote while only 66.67% of users gave SciSparc an outperform vote.
Summary
SciSparc beats Timber Pharmaceuticals on 8 of the 11 factors compared between the two stocks.
Get SciSparc News Delivered to You Automatically
Sign up to receive the latest news and ratings for SPRC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SPRC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SciSparc Competitors List
Related Companies and Tools
